Correspondence 0001493152-24-048695 from bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc.
Date: Dec. 4, 2024 · CIK: 0001712762 · Accession: 0001493152-24-048695
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283521
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Jane Park bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed November 27, 2024 File No: 333-283521
Dear Ms. Park:
bioAffinity Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-283521) (the “Registration Statement”), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Friday, December 6, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify Ms. Marlow when this request for acceleration has been granted.
Very
truly yours,
BIOAFFINITY
TECHNOLOGIES, INC.
Show Raw Text
CORRESP
1
filename1.htm
December
4, 2024
VIA
EDGAR
United
States Securities
and
Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Jane Park
Re:
bioAffinity
Technologies, Inc.
Registration
Statement on Form S-1
Filed
November 27, 2024
File
No: 333-283521
Dear
Ms. Park:
bioAffinity
Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration
Statement on Form S-1 (File No. 333-283521) (the “Registration Statement”), be accelerated by the U.S. Securities
and Exchange Commission (the “Commission”) to become effective on Friday, December 6, 2024, at 5:00 p.m.,
Eastern Time, or as soon as reasonably practicable thereafter.
The
Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware
of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration
Statement.
The
Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact
Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify Ms. Marlow when this request
for acceleration has been granted.
Very
truly yours,
BIOAFFINITY
TECHNOLOGIES, INC.
By:
/s/
Maria Zannes
Name:
Maria
Zannes
Title:
Chief
Executive Officer
cc:
Leslie
Marlow, Blank Rome LLP